Trial Profile

A Phase 1, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REM 422 (Primary)
Indications Adenoid cystic carcinoma
Focus Adverse reactions
Sponsors Remix Therapeutics

Most Recent Events

18 Feb 2026 The phase has been changed to phase 1\2 ,1 TU primary endpoint added.
24 Oct 2025 According to Remix Therapeutics media release, company announced positive preliminary results from its ongoing Phase 1 clinical trial evaluating REM-422.
24 Oct 2025 Planned number of patients changed from 65 to 100.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com